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 Prediabetes  Insulin resistance  b-cell dysfunction
 Dysglycemia  HyperinsulinemiaWhatever the definition of prediabetes may be, at present or in the future, its patho-
physiology is a direct extension of the physiology of glucose control. In fact, all
evidence indicates that progression to diabetes occurs along a continuum, not neces-
sarily linear with time, of glucose concentration and mechanisms; plasma glucose
thresholds, on the other hand, are practical clinical constructs, generally used for diag-
nosis and treatment. Therefore, it is appropriate, and equivalent, to describe the path-
ophysiology of prediabetes both in terms of continuous changes in glucose
parameters and as shifts in glucose tolerance category.
The glucose system is highly homeostatic, swinging in plasma glucose concentra-
tions rarely exceeding 3 mmol/L (54 mg/dL) in normal people. At any given time, the
plasma glucose concentration represents a balance between entry of glucose into
and exit from the circulation via cellular metabolism or excretion; excessive release
or defective removal (or combinations of the two) results in increasing glucose levels.
Entry and exit of glucose are subject to multiple regulatory mechanisms, with insulin
and glucagon principally controlling entry and insulin governing exit. The pathophys-
iology of prediabetes can therefore be reduced to the following questions: Is glucose
release abnormal? If so, is it because of changes in b-cell or a-cell function or hepatic
sensitivity to these hormones? Is glucose disposal abnormal? If so, is it caused by
b-cell dysfunction or changes in peripheral tissue sensitivity to insulin? Are there rela-
tionships between glucose release and removal?
A preliminary consideration is the unique organization of the insulin/glucagon
system. For many protein and nonprotein hormones, action is modulated by at least
1, often 2, hierarchical hormonal feedback pathway (eg, corticotropin-releasing
hormone and adrenocorticotropic hormone for cortisol, gonadotropin-releasing
hormone and gonadotropins for sex steroids). In these cases, sensitivity is provided
by the circulating hormone concentrations acting on specific hormone receptorsThe authors have nothing to disclose.
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Ferrannini et al328located on target tissues as well as on the master gland of the feedback loop (eg, the
pituitary). In the case of insulin and glucagon, there is no major pituitary or hypotha-
lamic relay; target tissues control secretion directly. Thus, the circulating concentra-
tions of substrates (mostly glucose, but also amino acids, free fatty acids [FFAs],
and ketone bodies), which result from insulin action on intermediary metabolism in
different tissues, feed signals back to the b-cell and the a-cell. Sensitivity gating is
provided by insulin and glucagon receptors on target tissues. An additional level of
regulation is paracrine in nature, ie, insulin receptors on the b-cell and the a-cell.
GLUCOSE RELEASE
Under normal circumstances of a short (10–14 hours) overnight fast, most glucose is
produced by the liver,1 with the kidneymaking amarginal contribution.2Within the liver,
glucose is both synthesized, in approximately equal parts from glycogenolysis and
gluconeogenesis,3 and taken up,4 such that what is eventually released into the blood-
stream is the net sumof these simultaneousprocesses.With the useof labeledglucose,
the amount of glucose released in the fasting state (endogenous glucose production,
EGP) can be measured with acceptable accuracy. In nondiabetic healthy men and
womenwith normal glucose tolerance (NGT) and in individualswith either impaired fast-
ing glucose (IFG, fasting glucose between 110–126 mg/dL [6.11–7.00 mmol/L]) and
a 2-hour glucose level less than 200 mg/dL (<11.1 mmol/L on a standard oral glucose
tolerance test [OGTT]) or impaired glucose tolerance (IGT, fasting glucose <126 mg/dL
[<7.0 mmol/L]) and a 2-hour glucose level of 140 to 199 mg/dL (7.8–11.1 mmol/L),
EGP is directly and linearly related to both fat-free mass and fasting plasma glucose
(FPG) concentration (Fig. 1). The mean values of the individuals with IFG/IGT fall toFig. 1. Relationship between EGP and fat-free mass (top) and FPG concentration (bottom).
The blue lines are best fits, and the dotted red lines are their 95% confidence intervals.
Mean and standard deviation for the group with NGT (n 5 355) and for the group with
IFG/IGT (n 5 38) are plotted. (Unpublished data from the RISC Study, Ferrannini E, Balkau
B, Coppack SW, RISC Investigators, et al. Insulin resistance, insulin response, and obesity
as indicators of metabolic risk. J Clin Endocrinol Metab 2007;92:2885–92.)
Pathophysiology of Prediabetes 329the right of those with NGT but on the same regression line. These relationships have
important implications. First, EGP appears to be geared to the mass of metabolically
active tissues: the larger the mass, the higher EGP. What drives this association is
not known. It is possible that, as fat-free mass increases in parallel with fat mass (eg,
during phases of weight gain, glucose consumption increases proportionately and
minimally), chronic reductions in blood glucose levels signal the liver to rev up glucose
release by autoregulation5; other metabolic factors, for example, circulating FFAs, may
be at work (see later). Second, as individuals with IFG/IGT frequently have higher body
mass index (BMI, calculated as the weight in kilograms divided by the height in meters
squared) than thosewithNGT (28.4 vs 25.8 kg/m2,P<.001, for the subjects inFig. 1) and
hence larger fat-free mass as part of their phenotype (see last section), their EGP tends
to be higher, especially in individuals with IFG. As a consequence, expressing EGP in
units (mmol/min) normalized for fat-free mass eliminates differences between groups
(15.7 vs 16.2 mmol.min1.kgffm1, P 5 .67). Third, if the adaptive changes in EGP
were perfect, FPG would be identical in individuals with IFG/IGT and in those with
NGT. As this is not the case—fasting glycemia is significantly, if slightly, higher in indi-
viduals with IFG/IGT than in those with NGT (97 vs 90 mg/dL [5.4 vs 5.0 mmol/L],
P<.0001)—the EGP response is maladaptive. The reason for this response is insulin
resistance. In fact, fasting plasma insulin concentrations are significantly higher in indi-
viduals with IFG/IGT than in those with NGT (9 vs 6 mU/mL (55 vs 36 pmol/L), P<.0001),
indicating that the ability of the hormone to restrain EGP is impaired. By using the
product of EGP (normalizedper kilogramof fat-freemass) and fasting insulin, anempiric
index that has been termed insulin resistance index and used in several studies,6 one
now finds a relatively strong general relationship between glucose output and fasting
glycemia (independent of body mass), along which the group with IFG/IGT are clearly
separated from that with NGT (895 vs 574 mmol.min1.kgffm1 pM, P<.001) (Fig. 2).
Once overt diabetes ensues, EGP further increases even in absolute terms, especially
in poorly controlled patients.7,8
During absorption of a glucose load or a mixed meal, EGP is substantially sup-
pressed in individuals with NGT,9 significantly less so in patients with diabetes.10
The situation in prediabetes is intermediate in that EGP is suppressed to normal abso-
lute levels but at higher prevailing plasma insulin concentrations; calculation of
a hepatic insulin resistance index under these circumstances indicates an impairment
in the ability of a stimulated insulin response to adequately block postprandial glucose
output.
In patients with diabetes, circulating glucagon levels are insufficiently inhibited by
the hyperglycemia and hyperinsulinemia that follow glucose or meal ingestion; in
fact, they may increase paradoxically.11,12 Furthermore, recent studies have shownFig. 2. Relationship between the hepatic insulin resistance (IR) index (calculated as the
product of EGP and fasting plasma insulin from the data in Fig. 1) and FPG concentration.
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tance in nondiabetic individuals.13 This finding can be interpreted as evidence that the
a-cell, which is richly equipped with insulin receptors, is less responsive to the inhib-
itory influence of the hormone in states of generalized insulin resistance such as
prediabetes.14 The hepatic sensitivity to glucagon, on the other hand, has been
reported to be preserved in patients with type 2 diabetes and presumably is similarly
intact in prediabetes, although the relative contribution of glycogenolysis and gluco-
neogenesis to EGP may be shifted in favor of the latter as a source of circulating
glucose.15
With regard to glucose uptake, the liver takes up circulating glucose (as does the
gut), but its contribution to overall glucose disposal, as assessed by the hepatic
vein catheterization technique4 and, more recently, by positron emission tomography
with 18F-fluorodeoxyglucose (18FDG-PET),16 is limited in humans. Although sensitive
to insulin,17 the liver mainly responds to hyperglycemia by a mass action effect.4,18
Studies using 18FDG-PET have shown that insulin-mediated glucose uptake by the
liver is impaired in patients with type 2 diabetes, in proportion to the severity of
hyperglycemia19; presumably, a lesser extent of impairment is present in prediabetes,
although this has not been directly determined in these patients. In contrast to
glucose, the liver extracts 2 to 3 times more circulating FFA (especially shorter-chain
FFA20) than resting muscle (as measured by PET [positron emission tomography] and
18F-6-thia-heptadecanoic acid21). Although liver FFA uptake is slightly reduced in
patients with IGT,22 hepatic oxidation of this substrate is increased in obese
patients.23 Because prediabetic individuals are often overweight or obese, enhanced
liver fat oxidation is likely another metabolic feature of prediabetes. FFAs do not
contribute net carbon to de novo glucose synthesis, but their oxidation stimulates
the activity of key gluconeogenic enzymes (pyruvate carboxylase, phosphoenolpyr-
uvate carboxykinase, glucose-6-phosphatase) as well as provides the energy for
the process.24 Furthermore, FFA inhibit liver glycolysis,25 thereby completing an intra-
hepatic substrate competition cycle analogous to the one described by Randle26 in
isolated skeletal muscle. The prediction that an augmented availability of FFA results
in a reduction in liver glucose uptake has in fact been verified in PET studies using an
exogenous lipid infusion to increase FFA delivery to the liver.27
In summary, in the liver of the prediabetic patients, insulin resistance is manifested
as a reduced ability of insulin to restrain glucose release, especially from gluconeo-
genesis, and to stimulate glucose uptake. Enhanced FFA flux, uptake, and oxidation
compete with glycolysis and stimulate gluconeogenesis, thereby adding a purely
metabolic component to the cellular defects in insulin action.28 In recent years, it
has become evident that body fat distribution is an additional factor in the control of
EGP (and in general, of liver function). Independent of total body fat mass, accumula-
tion of adipose tissue within the visceral/abdominal region and the liver is associated
with an accentuation of insulin resistance of gluconeogenesis.29 Inflammatory
changes in adipose depots and consequent release of inflammatory cytokines are
probable mechanisms for this effect.30GLUCOSE DISPOSAL
When assessed by the euglycemic clamp technique (and expressed as the total
amount of glucose used normalized by fat-free mass as well as steady-state clamp
insulin concentrations [M/I]), insulin sensitivity is found to be progressively impaired
from NGT to IFG to IGT to overt type 2 diabetes (Fig. 3). To emphasize the continuous
nature of the relationship between insulin sensitivity and glucose tolerance, Fig. 4
Fig. 3. Insulin sensitivity (as box plots of the M/I) in individuals with NGT, impaired fasting
glucose (IFG), IGT, and type 2 diabetes (T2D). Asterisks indicate a significant difference
from the NGT group. (Data from the RISC Study, Ferrannini E, Balkau B, Coppack SW, RISC
Investigators, et al. Insulin resistance, insulin response, and obesity as indicators of meta-
bolic risk. J Clin Endocrinol Metab 2007;92:2885–92.)
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adjusted for gender, age, and BMI; all else being equal, M/I decreases by approxi-
mately 11 units per each mmol/L increase in 2-hour plasma glucose concentrations.
Thus, peripheral insulin resistance is a central metabolic feature of prediabetes inde-
pendent of factors, such as gender, age, and obesity, which themselves affect insulin
action. Even within the realm of NGT, individuals with higher glucose increments
during a standard dynamic test such as the OGTT are more insulin resistant than those
whose glucose excursions are lower. Ethnicity may contribute to insulin resistance
independent of glucose tolerance and other determinants. In a study using the insulin
clamp technique, Mexican-Americans were shown to be more insulin resistant than
non-Hispanic whites, regardless of whether they were with NGT, IGT, or diabetes.31
With regard to the tissues responsible for impaired insulin-mediated glucose
uptake, skeletal muscle dominates because it typically represents approximately
40% of body weight.32 However, adipose tissue makes a significant contribution to
whole body glucose disposal, as demonstrated by an 18FDG-PET study,33 especially
in an overweight phenotype as the prediabetic individual. Moreover, in the adipocyte,Fig. 4. Reciprocal association between insulin sensitivity (as the M/I) and 2-hour plasma
glucose concentration on a standard OGTT. The relation shown by the solid line and its
95% confidence intervals is adjusted for center, sex, age, and BMI. T2D, type 2 diabetes.
(Data from the RISC Study, Ferrannini E, Balkau B, Coppack SW, et al, RISC Investigators.
Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endo-
crinol Metab 2007;92:2885–92.)
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which is necessary for FFA reesterification, resulting in excessive FFA net release
into the bloodstream. In turn, the augmented delivery of FFA to insulin target tissues
causes their preferential uptake over that of circulating glucose, thereby realizing
the classical Randle cycle.26 In fact, studies combining indirect calorimetry with the
clamp technique34 have demonstrated that lipid oxidation rates are increased and
glucose oxidation rates are correspondingly decreased in insulin-resistant individuals
both in the fasting state and during insulinization (clamp or OGTT), a phenomenon that
has been later renamed metabolic inflexibility.35 In the heart, this chronic shift in
substrate use imposes a preferential use of FFAs, which are more oxygen costly
than glucose as a fuel,36 a demand that may be undesirable under ischemic
conditions.37 Another consequence of insulin resistance on glucose oxidation is an
increase in the accumulation of lactate in the circulation, a hallmark of ischemia,
and reduced glycogen accumulation.34
Of note is that peripheral insulin resistance is influenced by fat distribution in the
same negative direction as hepatic insulin resistance.33 It is therefore not surprising
that peripheral and hepatic insulin resistances, when expressed in appropriate units,
are found to be quantitatively related to one another (Fig. 5), as is also the case
between skeletal and myocardial muscles.36 IFG and IGT differ somewhat in the rela-
tive severity of hepatic versus peripheral insulin sensitivity, the hepatic insulin sensi-
tivity being worse in IFG, peripheral insulin sensitivity in IGT.38 However, this
distinction is rather tenuous because IFG is associated with IGT in more than 60%
of the cases; isolated IFG is rare in the population and carries little population attribut-
able risk for diabetes.39
b-CELL FUNCTION
Plasma glucose concentrations increase minimally even in the presence of profound
insulin resistance as long as the b-cell response is adequate; the hyperglycemia
that defines prediabetes ensues when some critical aspect of b-cell function becomes
defective. The normal b-cell adaptive response to insulin resistance is an upregulation
of its set point: at each plasma glucose concentration absolute insulin secretion rates,
both in the fasting state and throughout an OGTT, are higher in insulin-resistant indi-
viduals than in insulin-sensitive individuals. In prediabetic individuals, the relationship
between insulin secretion and insulin sensitivity is a similar curvilinear function as inFig. 5. Log-log plot of the relationship between the hepatic insulin resistance (IR) index and
insulin sensitivity (as the M/I) for the subjects in Fig. 1.
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(Fig. 6). The higher plasma glucose levels, therefore, are not explained by a deficiency
in the absolute amount of secreted insulin. The cause of hyperglycemia is the reduced
ability of the b-cell to respond to increasing glucose levels in a timely fashion during
stimulation, which is clearly shown when plotting insulin secretion rates against
concomitant glucose levels: for each increment in glucose concentration during an
OGTT insulin secretion is less in prediabetic states than in NGT states (Fig. 7). Analo-
gous to the concept of insulin resistance, the slope of the relationship between insulin
secretion and glucose concentration is an expression of b-cell glucose sensitivity.40
Once again, the mechanism represents a continuum, from NGT to diabetes through
prediabetes.41
This dynamic aspect of b-cell function is crucial for 2 reasons: (1) it is largely inde-
pendent of insulin sensitivity and (2) it is tightly linked with glucose tolerance (Fig. 8).42
In fact, in the RISC study database43 both insulin resistance and b-cell glucose insen-
sitivity are independently associated with IFG/IGT: in a mutiple logistic regression
model adjusting for sex, age, and BMI, an M/I value in the lowest quartile of its distri-
bution carries an odds ratio of 3.7 (with a 95% confidence interval of 2.4–5.7), while
a value of b-cell glucose sensitivity in the bottom quartile carries an odds ratio of
5.1 (95% confidence interval: 3.5–7.6). Individuals falling into the bottom 25% of
both physiologic variables have a 9-fold increase in the likelihood of being prediabetic.
The codominant role of insulin resistance and b-cell glucose insensitivity in predicting
incident dysglycemia has been confirmed in an observational follow-up study of
a cohort enriched with individuals with a family history of diabetes.44
It should be noted that empiric indices of b-cell function, such as the acute insulin
response to intravenous glucose (AIR)45,46 and the insulinogenic index on the
OGTT,40,42 have also been used to signal defective b-cell function in prediabetes.
Although qualitatively related to b-cell glucose sensitivity, these indices are much
less sensitive in discriminating IFG/IGT from NGT (see Fig. 8).Fig. 6. Relationship between total insulin output over the 2 hours after glucose ingestion
and insulin sensitivity (as the M/I). The lines are the separate power function fit for the
NGT group and the IFG/IGT group. The intercept of the 2 lines are significantly different
(P<.001). (Data from the RISC Study, Ferrannini E, Balkau B, Coppack SW, et al, RISC Investi-
gators. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin
Endocrinol Metab 2007;92:2885–92.)
Fig. 7. Insulin secretion rates against concomitant plasma glucose concentrations during
a standard OGTT. The color areas encompass mean and standard error of the slope calcu-
lated for the 3 groups by mathematical modeling. (Data from Ferrannini E, Mari A. Beta
cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia
2004;47:943–56.)
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loss of glucose tolerance, that is, insulin resistance and b-cell glucose insensitivity,
tend to occur together in prediabetes as well as overt diabetes and to covary consen-
sually over time.44 It has therefore been natural to ask the question, whether there is
a structural link or cause-and-effect relationship between them. Knocking out insulin
receptors selectively in b-cells impairs glucose sensing of the isolated perfused pan-
creata from these mice.47 More recent studies have indicated that insulin potentiatesFig. 8. Reciprocal association between b-cell glucose sensitivity and mean plasma glucose
level during an OGTT (upper panel). For the NGT and IFG/IGT groups, the lower panel shows
(as box plots) values for the acute insulin response (AIR) to intravenous glucose, the insuli-
nogenic index (ratio of insulin-to-glucose increments 30 minutes into the OGTT), and b-cell
glucose sensitivity measured in the same group. The group difference is only significant for
the measure of b-cell glucose sensitivity. (Data from the RISC Study, Ferrannini E, Balkau B,
Coppack SW, et al, RISC Investigators. Insulin resistance, insulin response, and obesity as indi-
cators of metabolic risk. J Clin Endocrinol Metab 2007;92:2885–92.)
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mechanisms linking insulin signaling to glucose sensing in the b-cell remain to be clar-
ified, as do the in vivo circumstances under which this interaction becomes important.THE CLINICAL PHENOTYPE
The abnormalities of glucose concentrations and their determinants are part of
a constellation of subclinical abnormalities that consistently occur together in predia-
betic individuals. As compiled in Fig. 9, in comparison with NGT controls, patients with
IFG/IGT have a higher family history of diabetes, are slightly more often men than
women, are somewhat older, are definitely heavier, and have a more central distribu-
tion of body fat; values of heart rate and systolic and diastolic blood pressures are
higher as are serum lipid levels (low-density lipoprotein cholesterol, triglycerides,
and FFA), whereas high-density lipoprotein cholesterol concentrations are lower,
and hyperinsulinemia is present both in the fasting state and 2 hours after glucose
ingestion. Importantly, the strong association between insulin resistance and b-cell
glucose insensitivity with prediabetes resists statistical adjustment for the lipid and
hemodynamic abnormalities as well as familial diabetes. This finding supports the
notion that the genetic imprint conveyed by familial diabetes is phenotypically speci-
fied as the pathophysiologic mechanisms of hyperglycemia. In fact, multiple commonFig. 9. Mean clinical and metabolic characteristics of NGT and IFG/IGT individuals. The data
are arranged as graduated spokes, each representing a variable, along which the blue
square plots the mean value of the NGT group and the black dot that of the IFG/IGT group;
the profile results from connecting the 2 series of dots and filling it in light blue for the NGT
group and in red for the IFG/IGT group. The variables are men %, percentage of male
subjects; FHD %, percentage of persons with a positive family history of diabetes; age (in
years); BMI (in kg/m2); WHR, waist-to-hip ratio; HR, heart rate; SBP, systolic blood pressure;
DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol in mmol/L; HDL-C,
high-density lipoprotein cholesterol in mmol/L; and TG, triglycerides in mmol/L; FFAs in
mmol/L; FPG; 2-h PG, 2-hour plasma glucose on the OGTT in mmol/L; FPI, fasting plasma
insulin; 2-h FPI, 2-hour fasting plasma insulin on the OGTT in pmol/L; HIR, hepatic insulin
resistance index; M/I, insulin sensitivity from the clamp technique; and b-cell GS, b-cell
glucose sensitivity frommathematical modeling of the OGTT. (Data from the RISC Study, Fer-
rannini E, Balkau B, Coppack SW, et al, RISC Investigators. Insulin resistance, insulin response,
and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007;92:2885–92.)
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The clustering also suggests that insulin resistance/hyperinsulinemia may link dia-
betes with clinical hypertension and dyslipidemia either mechanistically or by genetic
linkage (or both).
Recent work has emphasized that the phenotype in Fig. 9 is closely predictive of
nonalcoholic fatty liver disease.51 A meta-analysis of available evidence has
concluded that prediabetes per se (IFG, IGT, or both combined) is associated with
a modest but significant increase in risk for cardiovascular disease.52SUMMARY
Prediabetes encompasses conventional diagnostic categories of IFG and IGT (or, in
the future, HbA1c
53) with thresholds subject to change, but actually is a band of
glucose concentrations and a temporal phase over a continuum extending from
conventional NGT to overt type 2 diabetes. Insulin resistance, at the level of the liver
and peripheral tissues, and defective glucose sensing at the b-cell are the central
pathophysiologic determinants that together cause and predict the defining hypergly-
cemia. Regardless of the cellular origin of the insulin resistance, excessive tissue fat
utilization is a consistent metabolic mechanism. Although genetic influences affect
b-cell function, becoming overweight is the main acquired challenge to insulin
action.54 The phenotype of prediabetes includes dyslipidemia and higher arterial
blood pressure, thereby representing a common soil of atherogenic risk.REFERENCES
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